Answers are grounded in this paper and cite their sources.
Heparanase, an endoglycosidase implicated in tumour growth, invasion, and metastasis, remains an attractive target for anticancer drug discovery. In this study, a series of indole-based hydrazones was designed to target heparanase with potential anticancer inhibition in breast cancer cells. Structure-based analyses, including molecular docking and molecular dynamics simulations, suggested that several derivatives can interact with residues in the heparanase binding region, including recurrent contacts involving GLU 225, GLN 270, HIS 296, TYR 298, and TYR 348. In silico ADME profiling indicated generally acceptable drug-like properties for the designed series. The designed compounds were synthesized and characterized by FTIR, 1 H NMR, 13 C NMR, and HRMS, and conformational features were further examined by DFT studies. Among the synthesized compounds evaluated for heparanase inhibition using the HTRF assay, derivative E showed the highest apparent inhibitory response; however, its activity remained substantially weaker than that of the reference inhibitor PG545 and lacked a clear dose-dependent trend, indicating only modest inhibitory potential. Furthermore, cytotoxicity testing in MCF-7 breast cancer cells identified compound A as the most active compound, with an IC 50 value of 2.078 µM. Overall, these results identify indole-based hydrazones as preliminary scaffolds for further optimization toward heparanase-related anticancer applications.
No takes yet. Share an insight, caveat, or question.
Padmapriya et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: